ALKERMES PUBLIC LIMITED COMPANY

Alkermes plc is a global biopharmaceutical company that harnesses deep neuroscience expertise to create medicines for people living with complex psychiatric and neurological disorders. By combining rigorous scientific research with a compassionate, patient-focused approach, Alkermes develops and delivers FDA-approved treatments while advancing a robust pipeline of investigational candidates.

Key products include the once-daily oral antipsychotic olanzapine-samidorphan, approved for adult schizophrenia and bipolar I disorder, and the orexin-2 receptor agonist Alixorexton, currently in phase 2 trials for narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia. Early-stage programmes such as ALKS 4510 and ALKS 7290 explore novel orexin-based therapies for central nervous system conditions. The company's state-of-the-art manufacturing hub in Wilmington, Ohio, underpins its ability to supply high-quality medicines worldwide.

Alkermes is recognised as an employer of choice within the life-sciences sector and remains committed to translating scientific insight into real-world impact for patients and their families.